Collectively, our findings suggest that the co-expression of CXCR5 and CCR6 confers a distinct advantage, providing synergistic anti-tumor effects over the single expression of either receptor in HER2-CAR T cells. The gene discussed is ERBB2; the disease is neoplasm.